LAFRANCOL Quality and Innovative Pharmaceutical Products Since 1911
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 1/40
LAFRANCOL
Quality and Innovative PharmaceuticalProducts Since 1911
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 2/40
Company Overview
Founded in 1911
Successfully distributed French pharmaceutical
products in Latin America - bulk imports, packaging
and distribution.
In 1945, Lafrancol opens its first plant becoming the
first manufacturer of pharmaceuticals in Colombia
Continuous modernization has resulted in one of the
most modern plants in Latin America.
Today, Lafrancol is the #1 Pharmaceutical
Company in Colombia
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 3/40
MARKET POSITION
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 4/40
A commitment to providing quality products has established
Lafrancol as a leader in its markets:
# 1 Pharmaceutical company in sales (including multi-nationals)1
# 3 Pharmaceutical company in prescriptions2
# 1 Pharmaceutical company in new products for the last 10 years1
# 2 Pharmaceutical Company in the hormonal market1
Only Pharmaceutical Company with an Anti_TNF Biocompetitor
product worldwide (except China)
Source: 1. IMS MAT_Dec_2011 2. Close_Up MAT_Dec_2011
Lafrancol: Premiere Enterprise
DATA
DATA
DATA
DATA
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 5/40
Lafrancol ranks first in sales volume (including multi-nationals), in the ethical market without
milk top ten companies, with 11.92% growth, and posted the largest market gain in the
industry.Source: IMS MAT_Dec_2011
Snapshot - Leading Manufacturers
0
20,000,000,000
40,000,000,000
60,000,000,000
80,000,000,000
100,000,000,000
120,000,000,000
140,000,000,000
160,000,000,000
180,000,000,000
200,000,000,000
L
a f r a n c o l
B a y e r P h a r m a c e u t i c
P f i z e r
M s d
S a n o f i
A v e n t i s
G e n f a r
M
c k e s s o n
P r o c a p s
G l a x o s m
i t h k l i n e
B o e
h r
i n g e r
I n g
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 6/40
Rank 17
Rank 13
Rank 7
Rank 3
Rank 1
Rank 1
Ranking in IMS and Sales growth
20%3%
17%
29%
26%
26%11%
41%
38%
22%
3%5%
19%
Source: IMS Top Manufacturers 1999-2011 Ethical Market Without Milk / Internal Sales Data
Rank 1
Long-term – Aggressive Growth to the Top
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 7/40
Top Ten Laboratories in the Total Market– Market Share %
Source: IMS December 2011
Lafrancol – Overtaking the Multinationals
2,00%
3,00%
4,00%
5,00%
6,00%
7,00%
M T H e n e / 1 0
M T H f e b / 1 0
M T H m a r / 1 0
M T H a b r / 1 0
M T H m a y / 1 0
M T H j u n / 1 0
M T H j u l / 1 0
M T H a g o / 1 0
M T H s e p / 1 0
M T H o c t / 1 0
M T H n o v / 1 0
M T H d i c / 1 0
M T H e n e / 1 1
M T H f e b / 1 1
M T H m a r / 1 1
M T H a b r / 1 1
M T H m a y / 1 1
M T H j u n / 1 1
M T H j u l / 1 1
M T H a g o / 1 1
M T H s e p / 1 1
M T H o c t / 1 1
M T H n o v / 1 1
M T H d i c / 1 1
Lafrancol - (232) Bayer Pharmaceutic - (70) Nestle - (17) Glaxosmithkline - (88)
Msd - (91) Pfizer - (83) Abbott - (60) Mckesson - (185)
Sanofi Aventis - (86) Genfar - (150)
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 8/40
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 9/40
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 10/40
THE LAFRANCOL
ADVANTAGE
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 11/40
Experienced workforce of 2,500+ employees 40% in Research and Manufacturing.
60% Sales and Marketing.
Strongest & most aggressive sales force in Colombia.
Largest medical sales force Top selling sales force for last 10 years.
Proven team as demonstrated by the most successful new product launches in the
industry over the last 10 years.
Aggressive operation with 45,000+ sales visits per month to physicians.
Rapid market penetration Via successful marketing & distribution strategies.
Resulting in highest market share gains in the industry.
Advantage:
Sales & Marketing
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 12/40
Physicians Continued Medical Education and Educational University Grants
Distribution Excellent Relationships with Wholesalers, Distributors, Private & Government Entities and Pharmacies.
Patients Through“Health Centers” and Call Centers, patients are provided support on product information, adherence to
therapies and medicines, how to change their nutritional habits and adhere to new habits to achieve a better quality oflife.
Patient Care Programs (Cuidarte) : Focuses on assisting and educating patients using biotech
and specialty care products by assisting patients with:
At-home drug application.
Patient and nurse training.
Biosecurity training.
Pharmacovigilance program & pharmaceutical care.
Follow-up evaluations on adherence and patient satisfaction .
Advantage:
Pervasive Relationships
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 13/40
Advantage:
Specialized Studies
The only national pharmaceutical company with more than
30 studies in specialized areas:
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 14/40
Modern plants equipped with the latest technology and providing flexibleproduction capabilities.
o Cali, Colombia: 23,000 m2 modern, state-of-the-art manufacturing facility.
o Colombian Duty-Free Zone: 2,100 m2 manufacturing facility.
Leader in social and environmental responsibility.
Each plant operates under the most stringent quality control, as defined byinternational standards, including:
o
GMP (Good Manufacturing Practices for Pharmaceuticals).o ISO (International Organization for Standardization) 9001.
o ISO (International Organization for Standardization) 28000.
o PIC (Pharmaceutical Inspection Convention).
o FDA plant compliance is currently in process.
Advantage:
Manufacturing
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 15/40
PRODUCTS
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 16/40
Product Types
Injectables - Hormones
Tablets
Capsules
Granulates Ointments
Creams
Gels
Syrups
Sachets
Powders
Sterile Liquids
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 17/40
Product Lines
Branded Rx
Generics
Specialty Care: High Cost and Institutional(Private & Government)
Biotech, Oncology, & HIV
OTC
Pharmaceuticals, Nutraceuticals andFunctional Foods
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 18/40
Therapeutic Lines
NOTE: To view products click on image
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 19/40
SALES OPERATIONS
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 20/40
Offices in Colombia
Bogotá Corporate
Medical Research
Marketing
Sales
Cali
Operations & Production
Financial
Regional Offices
Sales & Marketing Sales Force for Physicians
Health Club for Patients
Health Nutritional Institute
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 21/40
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 22/40
International Operations
Exports Performance
0
2.000.000
4.000.000
6.000.000
8.000.000
10.000.000
12.000.000
14.000.000
2007 2008 2009 2010 2011
Values & Growth
54%26%
54%
19%
56%
Source: Internal Data on File
USD
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 23/40
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 24/40
Therapeutic Lines
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 25/40
Therapeutic Lines
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 26/40
Therapeutic Lines
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 27/40
Therapeutic Lines
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 28/40
Therapeutic Lines
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 29/40
Therapeutic Lines
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 30/40
Therapeutic Lines
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 31/40
Therapeutic Lines
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 32/40
Therapeutic Lines
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 33/40
Lafrancol : Market Leader
Total MarketSales - Total Market
(General Configuration: IMS Struct / Active to: Historical / Cut Off: 10 Rows / Filters: No / )
Local Currency Local Currency Units
MAT dic/11 MAT dic/11 MTH dic/11 MAT dic/11 MTH dic/11
Total Selected Accumulated 3,992,954,038,423 365,775,183,353 328,289,091 29,893,534
1 Lafrancol - (243) 6.1% 244,691,755,462 21,325,479,938 24,520,108 2,007,286
2 Glaxosmithkline - (104) 11.1% 198,981,237,527 15,791,894,250 15,403,599 1,230,079
3 Pfizer - (93) 15.5% 175,138,272,715 15,315,026,876 5,152,909 431,994
4 Bayer Pharmaceutic - (73) 19.7% 169,561,079,791 18,842,510,839 7,642,966 1,013,321
5 Msd - (99) 23.9% 164,220,469,542 15,342,459,853 7,369,966 756,727
6 Nestle - (17) 27.8% 157,160,826,861 15,900,248,974 9,893,256 986,461
7 Abbott - (65) 31.6% 151,883,692,303 14,292,667,004 9,280,479 881,599
8 Sanofi Aventis - (87) 35.3% 149,788,666,968 12,831,109,940 5,581,281 490,891
9 Mckesson - (190) 38.7% 132,223,018,131 13,226,631,898 22,231,407 2,206,092
10 Boehringer Ing - (54) 41.6% 117,870,674,910 10,250,202,520 8,213,799 689,827
Others (330) 100.0% 2,331,434,344,213 212,656,951,261 212,999,321 19,199,257
Source: IMS MAT_Dec_11
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 34/40
Lafrancol : Hormonal Market
Segment AnalysisSales - G
(General Configuration: IM S Struct / Active to: Historic al / CutOff: 10 Rows / Filters: No / )
Local Currency Local Currency Units
MTH dic/11 MAT dic/11 MTH dic/11 MAT dic/11 MTH dic/11
Total Se lected Accumulated 398,709,673,120 39,294,770,911 31,011,598 3,008,393
1 Bayer Pharmaceutic - (30) 30.6% 92,434,124,903 12,038,935,449 4,761,064 732,663
2 Lafrancol - (31) 46.8% 70,215,787,546 6,355,843,398 6,651,239 591,501
3 Pfi zer - (14) 51.2% 20,145,343,167 1,730,375,162 1,000,892 78,084
4 Sanofi Aventis - (8) 55.6% 21,692,234,350 1,706,986,815 1,107,910 92,839
5 Boehringer Ing - (5) 59.8% 19,803,995,130 1,674,235,513 885,946 68,554
6 Gynopharm - (16) 63.7% 15,667,995,808 1,515,141,064 794,234 65,787
7 Profamilia - (9) 67.3% 17,270,354,487 1,405,539,744 1,483,500 120,582
8 Lilly - (2) 70.1% 11,693,206,576 1,133,078,350 192,844 18,064
9 Tecnofarma - (8) 72.1% 8,812,067,156 784,337,737 135,659 12,084
10 Bayer Consume Care - (2) 74.1% 8,819,688,802 781,050,720 565,746 48,386
Others (95) 100.0% 112,154,875,195 10,169,246,959 13,432,564 1,179,849
Source: IMS MAT_Dec_11
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 35/40
Lafrancol : New Products
Source: IMS Colombia Dec_11
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 36/40
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 37/40
Advantage:Special Studies
APLAR, Taiwan 2.011
EULAR. Londres 2.011
American College of Rheumathology, Atlanta 2.010
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 38/40
Advantage:Special Studies
8/13/2019 Business Presentation Internacional
http://slidepdf.com/reader/full/business-presentation-internacional 39/40
Advantage:
Special Studies